1. Formulation and characterization of ionically crosslinked gellan gum hydrogels using trilysine at low temperatures for antibody delivery.
- Author
-
Villarreal-Otalvaro C, Gupta S, Dorn RW, Delaney JT Jr, Koppolu B, and Coburn JM
- Subjects
- Humans, Cell Survival drug effects, Drug Delivery Systems, Temperature, Fibroblasts drug effects, Fibroblasts metabolism, Antibodies chemistry, Hydrogels chemistry, Hydrogels pharmacology, Polysaccharides, Bacterial chemistry, Lysine chemistry, Cross-Linking Reagents chemistry
- Abstract
Research of the nontraditional polysaccharide gellan gum (GG) is a growing space for the development of novel drug delivery systems due to its tunable physic-mechanical properties, biocompatibility, and stability in a wide range of environments. Unfortunately, high temperature crosslinking is often required, representing a limiting factor for the incorporation of thermosensitive therapeutic agents. Here, we demonstrated that GG can be crosslinked at a low temperature (38 °C) using a simple fabrication process that utilizes trilysine as an alternative to traditional mono- or divalent ion crosslinkers. While elevated temperature mixing is still required to form a clear GG solution, crosslinking of 0.5 - 1 % GG (w/v) in the presence of trilysine (0.03 % - 0.05 % w/v) was achieved at 38 °C resulting in hydrogels with suitable working formulations to facilitate syringe loading. Low injection forces (< 20 N), and biocompatibility was evaluated with normal human dermal fibroblast (cell viability > 90 %). Frequency sweep showed a transition from purely liquid-like behavior to gel-like behavior with increased trilysine concentration. A temperature dependent behavior was lost with higher trilysine concentrations, indicating stable hydrogel formation. NMR results suggest that trilysine participates in gelation via both ionic interactions between the primary amines of trilysine and the carboxylate residues of glucuronic acid and hydrogen bonding. Released studies showed that GG hydrogels can entrap and provide sustained release of IgG in relation to the crosslinker, and antibody concentration used, with a burst release within the first 24 h (∼80 % cumulative released) followed by a sustained released for up to 5 days. Overall, findings demonstrate a promising nontoxic injectable hydrogel that requires lower crosslinking temperatures, is simple to manufacture and serves as a carrier of thermosensitive therapeutic agents., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Jeannine M. Coburn reports financial support was provided by Worcester Polytechnic Institute. Carolina Villarreal-Otalvaro reports a relationship with Boston Scientific Corporation that includes: employment. Joseph T. Delaney reports a relationship with Boston Scientific Corporation that includes: employment. Rick W. Dorn reports a relationship with Boston Scientific Corporation that includes: employment. Bhanu Koppolu reports a relationship with Boston Scientific Corporation that includes: employment. Carolina Villarreal-Otalvaro has patent #Therapeutic Hydrogels (US2022/0313603 A1) pending to Boston Scientific Corporation. Bhanu P. Koppolu has patent #Therapeutic Hydrogels (US2022/0313603 A1) pending to Boston Scientific Corporation. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF